Promises and challenges of the first clinical-grade induced pluripotent stem cell bank.

摘要: It has only been approximately 6 years since Shinya Yamanaka, a Japanese scientist from Kyoto University, found way of reverting differentiated cells an adult into embryoniclike pluripotent state [1]. These cells, termed induced stem (iPS) are as powerful human embryonic (hES) cells; they can be expanded infinitely, and upon differentiation provide unlimited number for autografts or close HLA-matched recipients, completely avoiding significantly reducing the host immune response need immunosuppression. Importantly, obtained by simple, minimally invasive procedures, such phlebotomy hair plucking, which free ethical issues that plague hES cell field. For his revolutionary work, Yamanaka was awarded Nobel Prize in 2012. Following this major breakthrough regenerative medicine everybody, including government funding agencies, jumped on iPS bandwagon. In July 2011, Innovative Medicines Initiative, Europe’s largest public–private initiative, launched call generation banks drug discovery safety assessment. The California Institute Regenerative Medicine is intending to build bank containing several thousand lines distribution researchers, while UK its own plans too. However, cell-based therapy not considered any these cases. Most will derived people with various diseases order study disease pathophysiology. Yet, spite insufficient knowledge about nature unresolved technical issues, labor-intensive methodology prohibitive costs, supported government, recently revealed therapeutic use [2]. This 75 carefully selected HLA haplotypes would match nearly 80%